NYSE:ZYME Zymeworks (ZYME) Stock Price, News & Analysis $10.75 +0.12 (+1.13%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$10.63▼$11.0150-Day Range$8.36▼$10.6352-Week Range$6.01▼$13.14Volume253,474 shsAverage Volume605,870 shsMarket Capitalization$760.13 millionP/E RatioN/ADividend YieldN/APrice Target$12.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrends Get Zymeworks alerts: Email Address Zymeworks MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside17.8% Upside$12.67 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews Sentiment0.64Based on 7 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.23) to ($0.97) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.86 out of 5 starsMedical Sector845th out of 936 stocksPharmaceutical Preparations Industry398th out of 436 stocks 2.3 Analyst's Opinion Consensus RatingZymeworks has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageZymeworks has only been the subject of 3 research reports in the past 90 days.Read more about Zymeworks' stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for ZYME. Previous Next 0.0 Dividend Strength Dividend YieldZymeworks does not currently pay a dividend.Dividend GrowthZymeworks does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ZYME. Previous Next 2.6 News and Social Media Coverage News SentimentZymeworks has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Zymeworks this week, compared to 2 articles on an average week.Search InterestOnly 2 people have searched for ZYME on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat Follows1 people have added Zymeworks to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Zymeworks insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.22% of the stock of Zymeworks is held by insiders.Percentage Held by Institutions92.89% of the stock of Zymeworks is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Zymeworks' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Zymeworks are expected to grow in the coming year, from ($1.23) to ($0.97) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Zymeworks is -6.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Zymeworks is -6.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioZymeworks has a P/B Ratio of 1.62. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Zymeworks' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has led to a massive bull run in the year after it happens. That means we're in the "golden window" right now…Check out the new "Crypto Bull Run Millionaire Blueprint" now! About Zymeworks Stock (NYSE:ZYME)Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.Read More ZYME Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ZYME Stock News HeadlinesJuly 25 at 4:30 PM | globenewswire.comZymeworks Appoints Leone Patterson as Chief Business and Financial OfficerJuly 22, 2024 | markets.businessinsider.comFDA Clears IND Application Of Zymeworks For ZW191July 27, 2024 | Monument Traders Alliance (Ad)This student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... In fact, it just detected a move happening this MONDAY.July 22, 2024 | marketwatch.comZymeworks Shares Rise After FDA Clears Cancer Drug ApplicationJuly 22, 2024 | globenewswire.comZymeworks Announces FDA Clearance of Investigational New Drug Application for ZW191, a Novel Folate Receptor-⍺ Targeted Topoisomerase I Inhibitor Antibody-Drug ConjugateJuly 11, 2024 | globenewswire.comZymeworks To Report Second Quarter 2024 Financial Results and Host Conference Call on August 1, 2024July 9, 2024 | seekingalpha.comZymeworks: A Somewhat Complicated StoryJune 17, 2024 | globenewswire.comZymeworks Announces FDA Clearance of Investigational New Drug Application for ZW171, a novel 2+1 T-cell Targeting Bispecific Antibody for Mesothelin-expressing CancersJuly 27, 2024 | Monument Traders Alliance (Ad)This student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... In fact, it just detected a move happening this MONDAY.June 10, 2024 | globenewswire.comZymeworks Announces China NMPA Acceptance of Biologics License Application for Zanidatamab for Second-Line Treatment of Biliary Tract CancerMay 29, 2024 | markets.businessinsider.comZymeworks Inc. (ZYME) Shareholders May Have Been Affected by Fraud- Levi & Korsinsky InvestigatesMay 28, 2024 | globenewswire.comZymeworks Announces Participation in Upcoming Investor ConferencesMay 21, 2024 | finance.yahoo.comZymeworks Provides Corporate Update and Reports First Quarter 2024 Financial ResultsMay 21, 2024 | finance.yahoo.comZymeworks Inc. (NASDAQ:ZYME) Consensus Forecasts Have Become A Little Darker Since Its Latest ReportMay 16, 2024 | businesswire.comKirby McInerney LLP is Investigating Potential Shareholder Claims Against Zymeworks Inc. (ZYME)May 9, 2024 | markets.businessinsider.comStifel Nicolaus Reaffirms Their Buy Rating on Zymeworks (ZYME)May 8, 2024 | markets.businessinsider.comHold Rating on Zymeworks: Balancing Potential Rewards and Valuation RisksMay 7, 2024 | benzinga.comZymeworks Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)See More Headlines Receive ZYME Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zymeworks and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/02/2024Today7/26/2024Next Earnings (Confirmed)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNYSE:ZYME Previous SymbolNASDAQ:ZYME CUSIPN/A CIK1403752 Webwww.zymeworks.com Phone(302) 274-8744Fax604-737-7077Employees460Year FoundedN/APrice Target and Rating Average Stock Price Target$12.67 High Stock Price Target$16.00 Low Stock Price Target$10.00 Potential Upside/Downside+17.8%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.79) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-118,670,000.00 Net Margins-249.63% Pretax Margin-253.36% Return on Equity-28.37% Return on Assets-21.98% Debt Debt-to-Equity RatioN/A Current Ratio6.92 Quick Ratio6.92 Sales & Book Value Annual Sales$76.01 million Price / Sales10.00 Cash FlowN/A Price / Cash FlowN/A Book Value$6.63 per share Price / Book1.62Miscellaneous Outstanding Shares70,710,000Free Float69,842,000Market Cap$760.13 million OptionableOptionable Beta1.15 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Kenneth H. Galbraith C.A. (Age 61)CEO & Chairman of the Board Comp: $1.04MDr. Christopher Astle Ph.D. (Age 43)Senior VP & CFO Comp: $682.22kDr. Paul Moore Ph.D. (Age 56)Chief Scientific Officer Comp: $872.67kMr. Mark Hollywood (Age 54)Executive VP and Head of Technical & Manufacturing Operations Mr. Daniel Dex J.D.Ph.D., Senior VP, Corporate Secretary & General CounselDiana PapoveSenior Manager of Corporate CommunicationsDr. Lindsey Foulkes B.Sc.Ph.D., Vice President of Corporate DevelopmentMs. Laura O'ConnorVice President of Human Resources & DEIDr. Jeffrey Smith M.D.Executive VP & Chief Medical OfficerDr. Josemund Menezes MBBSManaging Director of Early-Stage Development for Asia PacificMore ExecutivesKey CompetitorsBausch Health CompaniesNYSE:BHCSpringWorks TherapeuticsNASDAQ:SWTXAmneal PharmaceuticalsNASDAQ:AMRXDeciphera PharmaceuticalsNASDAQ:DCPHProtagonist TherapeuticsNASDAQ:PTGXView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 14,825 shares on 7/26/2024Ownership: 0.438%SummerHaven Investment Management LLCBought 1,772 shares on 7/24/2024Ownership: 0.128%SG Americas Securities LLCSold 6,840 shares on 7/12/2024Ownership: 0.015%Farallon Capital Management LLCSold 155,000 shares on 5/24/2024Ownership: 2.264%California State Teachers Retirement SystemBought 1,215 shares on 5/16/2024Ownership: 0.061%View All Insider TransactionsView All Institutional Transactions ZYME Stock Analysis - Frequently Asked Questions How have ZYME shares performed this year? Zymeworks' stock was trading at $10.39 on January 1st, 2024. Since then, ZYME shares have increased by 3.5% and is now trading at $10.75. View the best growth stocks for 2024 here. How were Zymeworks' earnings last quarter? Zymeworks Inc. (NYSE:ZYME) announced its quarterly earnings results on Thursday, May, 2nd. The company reported ($0.42) earnings per share for the quarter, missing analysts' consensus estimates of ($0.31) by $0.11. The company had revenue of $10.03 million for the quarter, compared to the consensus estimate of $17.98 million. Zymeworks had a negative trailing twelve-month return on equity of 28.37% and a negative net margin of 249.63%. What is Ali Tehrani's approval rating as Zymeworks' CEO? 9 employees have rated Zymeworks Chief Executive Officer Ali Tehrani on Glassdoor.com. Ali Tehrani has an approval rating of 100% among the company's employees. This puts Ali Tehrani in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 86.0% of employees surveyed would recommend working at Zymeworks to a friend. When did Zymeworks IPO? Zymeworks (ZYME) raised $65 million in an IPO on Friday, April 28th 2017. The company issued 4,500,000 shares at a price of $13.00-$16.00 per share. Citigroup, Barclays, Wells Fargo Securities and Canaccord Genuity acted as the underwriters for the IPO and Cormark Securities was co-manager. Who are Zymeworks' major shareholders? Top institutional investors of Zymeworks include Bank of New York Mellon Corp (0.44%), SummerHaven Investment Management LLC (0.13%) and SG Americas Securities LLC (0.01%). Insiders that own company stock include Ecor1 Capital, Llc, Kenneth Galbraith, Neil A Klompas, Neil Josephson, Paul Andrew Moore and Christopher Astle. View institutional ownership trends. How do I buy shares of Zymeworks? Shares of ZYME stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Zymeworks own? Based on aggregate information from My MarketBeat watchlists, some other companies that Zymeworks investors own include Advanced Micro Devices (AMD), Gilead Sciences (GILD), Just Energy Group (JE), NVIDIA (NVDA), Just Energy Group (JE), PayPal (PYPL) and Alibaba Group (BABA). This page (NYSE:ZYME) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredThe #1 Crypto for 2024 (3 Cent Coin)Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zymeworks Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zymeworks With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ZYME Stock Alerts